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Pterosin B prevents chondrocyte hypertrophy
and osteoarthritis in mice by inhibiting Sik3
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Kaori Fujita1, Yumi Itoh3, Masahiro Nakamura4, Hiroyuki Fuchino5, Nobuo Kawahara5, Naoshi Fukui6,
Akira Watanabe4, Tomoatsu Kimura2 & Noriyuki Tsumaki1
Osteoarthritis is a common debilitating joint disorder. Risk factors for osteoarthritis include
age, which is associated with thinning of articular cartilage. Here we generate chondrocyte-
speciﬁc salt-inducible kinase 3 (Sik3) conditional knockout mice that are resistant to
osteoarthritis with thickened articular cartilage owing to a larger chondrocyte population. We
also identify an edible Pteridium aquilinum compound, pterosin B, as a Sik3 pathway inhibitor.
We show that either Sik3 deletion or intraarticular injection of mice with pterosin B inhibits
chondrocyte hypertrophy and protects cartilage from osteoarthritis. Collectively, our results
suggest Sik3 regulates the homeostasis of articular cartilage and is a target for the treatment
of osteoarthritis, with pterosin B as a candidate therapeutic.
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A
rticular cartilage lubricates the ends of bones. Its loss can
ultimately result in osteoarthritis, a common debilitating
joint disorder that affects more than 15% of the
population over the age of 60 (refs 1,2). Common risk factors
for osteoarthritis include age, excess mechanical loading and
metabolic syndrome. The most apparent age-associated change is
the reduced thickness of articular cartilage3,4; however, whether
thinner cartilage is more susceptible to osteoarthritis is unclear.
Although extensive studies have revealed age-related molecular
changes in chondrocytes, the molecules that control thickness of
articular cartilage are unknown.
During development, epiphyseal cartilage at both ends of the
bone gives rise to articular cartilage and growth plate cartilage
after the formation of the secondary ossiﬁcation centre.
Chondrocytes express type II collagen (COL2) and type XI
collagen (COL11) during proliferation, but will ultimately stop
proliferation and undergo hypertrophy in epiphyseal cartilage.
Hypertrophic chondrocytes express type X collagen (COL10) and
matrix metalloproteinases (MMPs), which contribute to the
degradation of cartilage and replacement by bone. Articular
cartilage consists of two layers, a non-calciﬁed zone
and a calciﬁed zone, which are separated by the tidemark.
Chondrocytes in the non-calciﬁed zone express COL2 and
COL11, whereas chondrocytes in the calciﬁed zone express
COL10. However, chondrocytes in the non-calciﬁed zone express
COL10 and MMPs in osteoarthritic conditions5–7, suggesting
activation of the hypertrophy programme. Inhibiting these
hypertrophic changes has been shown to reduce the severity of
cartilage lesions in mouse osteoarthritis models6,8,9. Thus,
molecules that activate the hypertrophy programme might be
promising therapeutic targets for osteoarthritis drugs.
We previously reported that Sik3 knockout mice have delayed
chondrocyte hypertrophy in mice10. Here we show that SIK3 is
activated in human osteoarthritic cartilage, leading us to
hypothesize that Sik3 is important for the development of
osteoarthritis. However, Sik3 total knockout mice have severely
malformed skeletons and most die at birth10; therefore,
we generated tamoxifen conditional chondrocyte-speciﬁc Sik3
knockout mice. Deletion of Sik3 in adult mice causes thickening
of articular cartilage and resistance to surgically induced
osteoarthritis, a phenotype associated with reduced expression
of Col10 in the non-calciﬁed zone of articular cartilage. We screen
for compounds that inhibit SIK3 activity, identifying pterosin B as
a suppressor of Sik3 signalling. Intraarticular administration of
pterosin B protects the mice from osteoarthritic change and
Col10 expression. These results suggest that pterosin B is a
promising candidate for osteoarthritis drug development.
Results
Expression of phospho-SIK3 in osteoarthritic cartilage. We
investigated the expression of total SIK3 and phosphorylated
SIK3 at T163 (pSIK3), which is the active form of SIK3
(refs 11,12), in articular cartilage. Immunohistochemical analysis
revealed that total SIK3 was uniformly detected from the surface
to deep layer, whereas pSik3 was detected only in the deep layer
of normal articular cartilage (Supplementary Fig. 1a). On the
other hand, pSIK3 was expressed in the superﬁcial layer of
severely affected osteoarthritic articular cartilage (Supplementary
Fig. 1b). Moreover, the worse the OARSI grade13, the more cells
in the superﬁcial layers expressed pSIK3. These results suggest
that activation of SIK3 is related to osteoarthritis development.
Generation of inducible Sik3 conditional knockout mice. We
generated transgenic mice bearing the Col11a2-CreER construct,
in which the CreER gene is linked to chondrocyte-speciﬁc a2(XI)
collagen chain gene (Col11a2) promoter/enhancer sequences
(Supplementary Fig. 2a). We mated Col11a2-CreER transgenic
mice with Rosa26-stopﬂox-EYFP tester mice to prepare Col11a2-
CreER; Rosa26-stopﬂox-EYFP mice. On intraperitoneal injection
of tamoxifen, Col11a2-CreER; Rosa26-stopﬂox-EYFP mice showed
YFP ﬂuorescence exclusively in primordial cartilage in the limbs
and ribs of embryos at 14.5 days postcoitum, whereas Rosa26-
stopﬂox-EYFP mice showed no YFP ﬂuorescence (Supplementary
Fig. 2b). Col11a2-CreER; Rosa26-stopﬂox-EYFP mice treated with
tamoxifen showed YFP expression exclusively in articular
cartilage in knee joints at 16 weeks of age, whereas mice without
tamoxifen treatment showed no YFP expression (Supplementary
Fig. 2c). These results suggest that the Col11a2-CreER transgenic
allele can induce recombination at loxP sites speciﬁcally
in chondrocytes in a tamoxifen-dependent manner.
We next generated Sik3ﬂox/þ (Supplementary Fig. 3a) mice
and prepared Col11a2-CreER; Sik3ﬂox/ﬂox mice. Col11a2-
CreER; Sik3ﬂox/þ mice and Sik3ﬂox/ﬂox mice were used as
controls. We conﬁrmed that Sik3 was deleted in the chondrocytes
of Col11a2-CreER; Sik3ﬂox/ﬂox mice after administration of
tamoxifen (Supplementary Fig. 3b). Hereafter, we call tamoxifen-
treated Col11a2-CreER; Sik3ﬂox/ﬂox mice as Sik3D/D mice,
tamoxifen-treated Col11a2-CreER; Sik3ﬂox/þ mice as Sik3D/þ
mice and tamoxifen-treated Sik3ﬂox/ﬂox mice as Sik3f/f mice.
Deletion of Sik3 increases thickness of articular cartilage.
To analyse Sik3 function in articular cartilage after birth,
we treated mice with tamoxifen at 2 weeks of age and killed them
at 4 weeks of age (Fig. 1a). To trace the fate of Sik3D/D cells,
we performed this experiment on the Rosa26-stopﬂox-EYFP
background (Col11a2-CreER; Sik3ﬂox/ﬂox; Rosa26-stopﬂox-EYFP
mice). Histological sections were stained with toluidine blue and
von Kossa to identify total articular cartilage (non-calciﬁed zone
and calciﬁed zone) and the non-calciﬁed zone only. The thick-
nesses of total articular cartilage and the non-calciﬁed zone of
articular cartilage as well as that of growth plate cartilage were all
increased in Sik3D/D mice compared with Sik3D/þ mice (Fig. 1b).
In addition, the numbers of YFP-positive cells per surface in
articular cartilage and growth plate cartilage in Sik3D/D mice were
increased compared with those in Sik3D/þ mice (Fig. 1c). The
expression levels of Col2a1 and Acan did not differ between
pellets of Col11a2-CreER; Sik3ﬂox/ﬂox chondrocytes cultured in
the presence of tamoxifen and those in the absence of tamoxifen
(Supplementary Fig. 3c), suggesting that the amount of matrix
production per chondrocyte did not change. These results
collectively suggest that Sik3 deletion increased the population of
chondrocyte progenies, resulting in increased total amount of
matrix and increased cartilage thickness.
We hypothesized that the increased chondrocyte population in
Sik3D/D mice might be caused either by increased proliferation
rates or decreased removal rates of the cells. To analyse the
proliferation rates, we performed BrdU labelling and found that
Sik3 deletion had no effect on either articular or growth plate
cartilage (Supplementary Fig. 4a). BrdU-positive cells were absent
in articular cartilage in both Sik3D/D mice and Sik3D/þ mice for
the entire labelling period (3 h). On the other hand, immuno-
histochemical analysis showed that deletion of Sik3 almost
eliminated Col10 expression in articular and growth plate
cartilage (Fig. 1c), suggesting that the removal of chondrocytes
was compromised. Lineage tracing revealed that progenies of
Col11a2-marked YFP-positive chondrocytes expressed Col10 in
the hypertrophic zone of growth plate cartilage (Fig. 1cA, arrow)
and in the calciﬁed zone of articular cartilage (Fig. 1cB, arrow) in
control mice, but that Sik3-deﬁcient chondrocytes did not express
Col10 in either (Fig. 1cC and 1cD). Moreover, YFP-positive cells
were absent from the Col10-positive area in Sik3D/D mice
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(Fig. 1cC, dotted circle), suggesting that progenies of Sik3D/D
chondrocytes continued to express Col2 instead. We conﬁrmed
that Sik3-deﬁcient cells expressed Col2 and Sox9, but not Col10
in growth plate cartilage (Fig. 1d, bottom panels), indicating
that Sik3-deﬁcient cells remain chondrocytes. These results
collectively suggest that Sik3 deletion keeps the Col2-positive;
Col10-negative chondrocyte state, which increases the population
of Col2-positive; Col10-negative chondrocytes and thickening of
articular cartilage.
Sik3 deletion protects cartilage from osteoarthritis. We next
examined whether Sik3 deletion affected the development of
osteoarthritis in adult mice. We treated 7-week-old mice with
tamoxifen to prepare Sik3D/D and Sik3f/f mice, and subsequently
subjected their right knees to destabilized medial meniscus
(DMM) surgery or sham surgery (skin and joint capsule incision)
at 8 weeks of age. The mice were killed 8 weeks after the operation
(therefore at 16 weeks of age) and subjected to histological
analysis (Fig. 2a). The thickness of articular cartilage in
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Figure 1 | Phenotype of cartilage in mice lacking Sik3 after birth. (a) We injected Col11a2-CreER; Sik3ﬂox/ﬂox; Rosa26-stopﬂox-EYFP mice and Col11a2-CreER;
Sik3ﬂox/þ ; Rosa26-stopﬂox-EYFP mice with tamoxifen daily for 5 consecutive days beginning at 2 weeks of age and killed them at 4 weeks of age.
(b) Semiserial histological sagittal sections of proximal tibia stained with toluidine blue and von Kossa. Boxed regions are shown to the right. Thickness of
growth plate cartilage, total articular cartilage and non-calciﬁed articular cartilage at the vertex of the articular surface in the corresponding sections of the
weight-bearing area (indicated by arrows) were measured and are shown in the right graphs. n¼4 mice. (c) Semiserial sections of b were immunostained
for Col10 (red) and YFP (yellow). Blue colour is DAPI. Boxed regions indicated by A–D are shown to the right. The numbers of EYFP-positive cells per
360mm-surface in articular cartilage were counted and are shown in the right graph. Arrows, Col11a2-marked YFP-positive chondrocytes in Col10-positive
matrix in Sik3D/þ mice. Dotted circle, the Col10-positive area lacking YFP-positive cells in Sik3D/D mice; n¼4 mice. (d) Semiserial sections of b,c were
immunostained for Col2, Sox9, YFP and Col10. Boxed regions in the left panels (Col2) are shown in the right panels. The images are representative of two
independent experiments. Error bars denote means±s.d. *Po0.05 and **Po0.01 by the t-test. Scale bars, 100 mm.
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sham-operated knees in Sik3D/D mice was thicker than that in
Sik3f/f mice (Fig. 2b), conﬁrming that Sik3 deletion caused
thickening of articular cartilage in adult mice. DMM operation
caused less severe osteoarthritis in Sik3D/D mice than in Sik3f/f
mice (Fig. 2c). Immunohistochemical analysis showed that DMM
operation induced Col10 expression in the non-calciﬁed zone of
articular cartilage of Sik3f/f mice (Fig. 2d). Deletion of Sik3
reduced this induction, as indicated by the limited expression of
Col10 in the Sik3D/D mouse knee joint that received the DMM
operation. These results collectively suggest that deletion of
Sik3 in chondrocytes thickens articular cartilage and inhibits
activation of the hypertrophy programme to protect mice from
developing osteoarthritis.
We further examined whether Sik3 deletion in chondrocytes
affects extra-cartilage status, which could affect cartilage biology
and pathology. Body weights and locomotor activities indicated
by a rotarod performance test were not different between
Sik3ﬂox/ﬂox and Col11a2-CreER; Sik3ﬂox/ﬂox mice before or
8 weeks after administration of tamoxifen (Supplementary
Fig. 4b). Angiogenesis indicated by the amount of CD31-positive
endothelial progenitor cells in subchondral bone was also not
different between Sik3ﬂox/ﬂox and Col11a2-CreER; Sik3ﬂox/ﬂox
mice after administration of tamoxifen (Supplementary Fig. 4c).
These results suggest that Sik3 deletion in cartilage affected
cartilage biology and pathology autonomously.
Identiﬁcation of pterosin B as a Sik3 inhibitor. Because our
Sik3D/D mice data suggested that Sik3 could be a target for
treatment of osteoarthritis, we searched for compounds that
inhibit Sik3 activity. It is known that SIKs phosphorylate HDACs
and CREB-regulated transcription coactivators (CRTCs) to
translocate these molecules from the nucleus to cytoplasm, which
thus abolishes their function in the nucleus. HDAC inhibits
myocyte enhancer factor 2C (MEF2C), and CRTC activates CREB
in nuclei. We established a dual luciferase assay system to
monitor MEF2C and CRTC2 activities in HEK293 cells. We
screenedB2,500 compounds and found that pterosin B (Fig. 3a)
decreased MEF2C activity and increased CRTC2 activity14.
Pterosin B is an extract acquired from boiling Pteridium
aquilinum in water supplemented with sodium bicarbonate.
We then developed a method to synthesize pterosin B
(Supplementary Fig. 5a). Our synthesized pterosin B inhibited
MEF2C and activated CRTC2 in a dose-dependent manner in
HEK293 cells according to a luciferase assay system in which
luciferase activity was regulated by GAL4-fusion MEF2 or
GAL4-fusion CRTC2 (Supplementary Fig. 5b). These results
conﬁrmed that pterosin B and not some impurity in the extract
was responsible for the function. Further, we conﬁrmed that
pterosin B speciﬁcally inhibited Sik3 in ATDC5 cells
(Supplementary Fig. 5c). Thus, we used synthesized pterosin B
in the following experiments.
Western blot analysis showed that the addition of pterosin B
decreased the amounts of Sik3, phosphorylated Hdac4 and
phosphorylated Crtc1 in primary chondrocytes in a manner
similar to 4-OH tamoxifen in chondrocytes from Col11a2-CreER;
Sik3ﬂox/ﬂox mice (Fig. 3b).
Sik3 accelerates chondrocyte hypertrophy by anchoring Hdac4
to the cytoplasm and releasing Mef2c from inhibition by Hdac4
in the nucleus10. Mef2c accelerates the hypertrophy programme
in chondrocytes15. We examined whether pterosin B inhibits
hypertrophic differentiation of chondrocytes by performing pellet
culture of wild-type mouse primary chondrocytes in the presence
or absence of pterosin B for 4 weeks. The presence of pterosin B
decreased the expression levels of Col10, Mef2c and Alp in a dose-
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Figure 2 | Effects of Sik3 deletion on osteoarthritis development in
DMM-operated knees. (a) Protocol of experiments: 7-week-old mice were
intraperitoneally injected with tamoxifen for 5 consecutive days, had their
right knees subjected to DMM or sham surgeries, and were killed at 16
weeks of age. (b) Histology of proximal tibia in sham-operated knees.
Safranin O-fast green-iron haematoxylin staining. The thickness of articular
cartilage and growth plate cartilage are shown in the graph. t-test.
(c) Histology of articular cartilage of proximal tibia in DMM-operated
knees. Boxed regions are shown in the bottom panels. OARSI scores of
articular cartilage in sham- and DMM-operated knees are shown.
Two blinded scorers gave consistent results. Mann–Whitney test.
(d) Immunohistochemistry for Col10 in knees. Boxed regions in the top
panels are shown in the bottom panels. The percentage of lacunae
surrounded by Col10-positive matrix per total number of lacunae are shown
in the right graph. Tukey–Kramer post hoc test. Error bars denote
means±s.d. Numbers of mice examined are indicated at the bottom
of the graphs. *Po0.05 and **Po0.01. NS, not signiﬁcantly different.
Scale bars, 100mm.
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Figure 3 | Effects of pterosin B on chondrocyte differentiation in vitro. (a) Structure of pterosin B. (b) Primary chondrocytes prepared from Col11a2-CreER;
Sik3ﬂox/ﬂox mice were treated with vehicle, 0.5mM 4-OH tamoxifen or 300mM pterosin B for 5 days and subjected to western blot analysis. The images are
representative of two independent experiments. (c) Real-time RT–PCR expression analysis of marker genes in pellet culture of mouse primary chondrocytes
with pterosin B; n¼ 3 pellets. (d) Metatarsal primordial cartilage from Sik3þ /þ mice were organ-cultured in 300 mM pterosin B or vehicle. Metatarsal
primordial cartilage from conventional Sik3 knockout mice were used for the control. Semiserial histological sections were stained with safranin O-fast
green-iron haematoxylin and immunostained for Col2 and Col10. The percentage of Col10-postive area per total length in the axial direction is indicated;
n¼ 3 metatarsals. (e) Primary chondrocytes were treated with 100mgml 1 cycloheximide in the presence or absence of 300 mM pterosin B. Cells were
lysed after treatment for 0, 24 and 36 h, and cell lysates were subjected to western blot analysis for Sik3 and Gapdh. The images are representative of two
independent experiments. (f) Primary chondrocytes were incubated in the presence or absence of 1 mM MG132, 10 nM baﬁlomycin A1 or 300 mM pterosin
B for 36 h. Cell lysates were subjected to western blot analysis for Sik3 and Gapdh. The images are representative of two independent experiments. Error
bars denote the means±s.d. *Po0.05 and **Po0.01 by the Tukey–Kramer post hoc test. Scale bars, 100mm.
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these levels in pellet culture of Col11a2-CreER; Sik3ﬂox/ﬂox
chondrocytes (Supplementary Fig. 3c). It also signiﬁcantly
decreased Runx2 and Ihh expression levels (Fig. 3c), suggesting
that pterosin B inhibits prehypertrophy of chondrocytes as well.
On the other hand, we did not detect signiﬁcant changes in the
expression levels of Sox9, Col2a1 or Acan mRNAs in pellets with
pterosin B treatment (Fig. 3c), which resembles tamoxifen effects
in pellet culture of Col11a2-CreER; Sik3ﬂox/ﬂox chondrocytes
(Supplementary Fig. 3c). We suspect the expression levels of these
three factors did not increase when hypertrophy was inhibited by
Sik3 deletion or pterosin B, because the pellet culture samples
were mainly composed of Col2a1-expressing chondrocytes and
contained a limited population of hypertrophic chondrocytes.
Finally, pterosin B did not signiﬁcantly affect the expression of
catabolic enzymes, such as Mmp3, Mmp13, Adamts4 or Adamts5
(Supplementary Fig. 6a).
In addition, pterosin B increased the expression level of Prg4
(Fig. 3c), which encodes lubricin, in wild-type chondrocyte
pellets. A CBP-CREB interaction inhibitor partly abolished this
elevation of Prg4 expression, suggesting that pterosin B treatment
activates Prg4 expression, at least in part, through the CRTC/
CREB pathway (Supplementary Fig. 6b). We also conﬁrmed that
pterosin B inhibits chondrocyte hypertrophy in organ culture of
metatarsal primordial cartilage (Fig. 3d), as it reduced the area of
the Col10-positive region in organ-cultured primordial cartilage
of wild-type mice.
RNA-sequencing analysis of entire mRNA transcripts showed
that chondrocyte pellets cultured in the presence or absence of
pterosin B and cartilage tissues were clustered distinctly from
other tissues such as skin, bone, muscle, liver, kidney, small
intestine, testis, brain and spinal cord (Supplementary Fig. 7).
Real-time PCR with reverse transcription (RT–PCR) expression
analysis showed pterosin B did not signiﬁcantly change Col1a1
expression levels (Fig. 3c). These results suggest that pterosin B
regulates the differentiation of chondrocytes, but does not alter
the cellular phenotype to other types of cells. RNA sequencing
analysis (Supplementary Fig. 8) largely conﬁrmed the changes in
the expression of marker genes found by real-time RT–PCR
analysis (Fig. 3c). Gene Ontology term analysis demonstrated that
downregulated genes in pterosin B-treated cells were associated
with bone mineralization (Supplementary Table 1), agreeing with
the observation that pterosin B delays chondrocyte hypertrophy
and mineralization. In addition, KEGG (Kyoto Encyclopedia of
Genes and Genomes) pathway analysis indicated that hedgehog
signalling was attenuated by pterosin B. The inhibition of
hedgehog signalling attenuates the severity of osteoarthritis6.
Whether hedgehog signalling mediates effects of Sik3 on
osteoarthritis is unexplored.
We ﬁnally analysed how pterosin B affects SIK3 activity.
Western blot analysis showed that treatment with pterosin B
decreased the amount of Sik3 protein (Fig. 3b). This decrease was
accelerated in cells treated with cycloheximide, an inhibitor of
protein synthesis (Fig. 3e). We also found that MG132 increased
the amount of Sik3 protein, whereas baﬁlomycin A1 did not
(Fig. 3f). Combined, these results suggest that pterosin B induces
the degradation of Sik3 protein by a proteasomal pathway. SIK3 is
activated by phosphorylation at T163 (ref. 16) and inactivated by
phosphorylation at T411 or S493 (ref. 17). We recently found that
pterosin B upregulates the phosphorylation of SIK3 at T411 and
S493 in hepatocytes, which results in the suppression of SIK3
activity14. Whether phosphorylation at T411 or S493 is related to
SIK3 degradation in chondrocytes is for further study.
Pterosin B protects cartilage from osteoarthritis. We examined
whether pterosin B can control osteoarthritis development.
We performed DMM surgery on the right knees of 8-week-old
wild-type mice (Fig. 4a). We injected pterosin B or vehicle
solutions into the joint space of DMM-operated knees three times
a week for 8 weeks. We also injected the right knees of mice,
which were not subjected to operation with pterosin B or vehicle
using the same schedule. We killed the mice at 16 weeks of age.
OARSI scores were better in the pterosin B-treated knees with
DMM than vehicle-treated knees with DMM. The non-operated
knees treated with pterosin B looked normal and showed similar
OARSI scores with those of non-operated knees treated with
vehicle. These results suggest that pterosin B protects mice from
osteoarthritis development. Immunohistochemical analysis
showed that pterosin B treatment reduced the Col10 expression
activated by DMM in the non-calciﬁed zone of articular cartilage
(Fig. 4b). Pterosin B treatment did not signiﬁcantly change the
synovitis score in non-operated knees or DMM-operated knees
(Fig. 4c).
We also examined the effects of pterosin B on older mice. We
performed DMM surgery at 13 weeks of age and injected pterosin
B or vehicle solutions into the joint space of the DMM-operated
knees three times a week for 12 weeks (Fig. 4d). Again, OARSI
scores were better in the pterosin B-treated knees with DMM
than vehicle-treated knees with DMM (Fig. 4d). Pterosin B
treatment reduced Col10 expression in the non-calciﬁed zone of
articular cartilage DMM-operated knees (Fig. 4e).
Pterosin B inhibits hypertrophy of human chondrocytes. We
ﬁnally examined whether pterosin B inhibits hypertrophy of
human articular chondrocytes. Human articular chondrocytes
were subjected to pellets cultured in chondrogenic medium for 8
weeks. We further cultured the chondrocyte pellets in medium
containing BMP-2, GDF-5, 3,3,5-Triiodo-L-thyronine (T3) and
b-glycerophosphate for 2 weeks to induce hypertrophic differ-
entiation. Histological analysis of the pellets revealed that the
addition of pterosin B in the medium protected chondrocytes
from hypertrophy and mineralization (Fig. 5a). Real-time
RT–PCR analysis showed that pterosin B reduced the expression
levels of COL10A1 and ALP, did not change that of COL2A1 and
increased those of SOX9 and PRG4 (Fig. 5b).
We next examined the effects of pterosin B on chondrocytes
derived from human-induced pluripotent stem cells (hiPSCs). We
differentiated hiPSCs towards chondroyctes and subjected them
to suspension culture to produce cartilage particles for 8 weeks,
as we described previously18. The cartilage particles were further
cultured with pterosin B or vehicle in hypertrophic condition for
4 weeks. Pterosin B protected chondrocytes in the particles from
hypertrophy and mineralization, as indicated by histological
appearance, von Kossa staining, immunohistochemical staining
for COL10 (Fig. 5c) and the expression of marker genes (Fig. 5d).
These results collectively suggest that pterosin B inhibits
hypertrophic change of human articular chondrocytes and
hiPSC-derived chondrocytes.
Discussion
Here we show that genetic deletion of Sik3 or inhibition of the
Sik3 signal by pterosin B protected mouse cartilage from
osteoarthritic change caused by DMM. The mechanisms of the
protection appear as inhibition of activation of the hypertrophy
programme or elevation of the Prg4 expression level in articular
chondrocytes.
Although deﬁnite evidence is lacking, age-associated thinning
of articular cartilage is a suspect risk factor for the erosion of
articular cartilage in osteoarthritis3. The turnover of articular
cartilage, which should deﬁne the thickness of articular cartilage,
is not well understood. The developmental process of the
secondary ossiﬁcation centre raises the hypothesis that cells in
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10959
6 NATURE COMMUNICATIONS | 7:10959 | DOI: 10.1038/ncomms10959 | www.nature.com/naturecommunications
84
0



















































































































































Figure 4 | Effects of pterosin B on osteoarthritis development in DMM-operated knees. (a–c) Eight-week-old mice with DMM were treated with
pterosin B for 8 weeks. (a) Histology of articular cartilage of DMM-operated knees injected with pterosin B or vehicle. Safranin O-fast green-iron
haematoxylin staining. Boxed regions in the top panels are shown in the bottom panels. OARSI scores of articular cartilage in DMM-operated knees injected
with pterosin B or vehicle (black dots) are shown to the right. OARSI scoring was also done on non-operated knees injected with pterosin B or vehicle
(black triangles). Two blinded scorers gave consistent results. Representative data are shown; Mann–Whitney test. (b) Immunohistochemistry for Col10
in knees. Boxed regions in the top panels are shown in the bottom panels. The percentage of lacunae surrounded by Col10-positive matrix per total number
of lacunae is indicated. Tukey–Kramer post hoc test. (c) Histology of synovium; haematoxylin–eosin staining. Boxed regions in the top panels are shown in
the bottom panels. Synovitis scores in DMM-operated knees injected with pterosin B or vehicle (black dots) and in non-operated knees injected with
pterosin B or vehicle (black triangles); Mann–Whitney test. (d,e) Thirteen-week-old mice with DMM were treated with pterosin B for 12 weeks.
(d) Histology of articular cartilage of DMM-operated knees injected with pterosin B or vehicle. Safranin O-fast green-iron haematoxylin staining. Boxed
regions in the top panels are shown in the bottom panels. OARSI scores of articular cartilage in DMM-operated knees injected with pterosin B or vehicle are
shown to the right. Two blinded scorers gave consistent results. Representative data are shown; Mann–Whitney test. (e) Immunohistochemistry for Col10
in articular cartilage in DMM-operated knees injected with pterosin B or vehicle. White dotted lines indicate tidemarks. White arrow represents Col10
expression above the tidemark. The images are representative of two independent experiments. Number of mice examined is indicated at the bottom of the
graphs. *Po0.05 and **Po0.01. NS, not signiﬁcantly different. Scale bars, 100mm.
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the non-calciﬁed zone very slowly turn into cells that express
Col10 and reside in the calciﬁed zone, where they are
subsequently removed and replaced by subchondral bone.
A recent study using lineage tracing of Prg4-positive cells has
shown that cells in the deeper zone are the progeny of cells in the
non-calciﬁed zone19, supporting this hypothesis. The thickness
of articular cartilage decreases with age, probably due to an
increasing imbalance between the proliferation rate of non-
calciﬁed zone cells and the rate by which these cells turn into cells
that express Col10, reside in the calciﬁed zone and are ﬁnally
removed. In this study, we found that Sik3 deletion increased the
population of chondrocytes and thickened articular cartilage at
least in young mice. Examining the effects of Sik3 deletion on
age-associated osteoarthritis model in mice is for further study.
Independent research groups have conﬁrmed two types of
substrates for SIKs, CRTC (a coactivator for the cAMP response
element (CRE)-binding protein (CREB)] and class IIa histone
deacetylase (HDAC)20. SIKs phosphorylate these two substrates
to induce nuclear export, resulting in a loss of the substrates’
transcriptional regulatory activities21,22. Sik3 anchors Hdac4 in

























































































































































































Figure 5 | Effects of pterosin B on human articular chondrocytes and hiPSC-derived chondrocytes. (a) Semiserial histological sections of cultured pellets
of human articular cartilage in the presence or absence of 300 mM pterosin B were stained with safranin O-fast green-iron haematoxylin and von Kossa and
immunostained for COL10. Boxed regions in the left panels are shown in the right. Area of von Kossa-positive regions per total area of pellets are shown;
n¼ 3 pellets. (b) Real-time RT–PCR expression analysis of marker genes in pellet culture of human articular chondrocytes in the presence or absence of
300mM pterosin B; n¼ 3 pellets. (c) Semiserial histological sections of hiPSC-derived cartilage particles treated with or without 300mM pterosin B were
stained with safranin O-fast green-iron haematoxylin and von Kossa and immunostained for COL2 and COL10. Boxed regions in the left panels are shown in
the right. The images are representative of three pellets each. (d) Real-time RT–PCR expression analysis of marker genes in hiPSC-derived cartilage
particles in the presence or absence of 300mM pterosin B; n¼ 3 pellets. Error bars denote means±s.d. *Po0.05, **Po0.01 and NS, not signiﬁcantly
different by the t-test. Scale bars, 100 mm.
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the cytoplasm to release Mef2c from inhibition by Hdac4, thus
activating the hypertrophy programme in the nuclei of growth
plate cartilage10,15,23. It has been reported that HDAC4 is
decreased in osteoarthritis cartilage, which may contribute to the
pathogenesis of osteoarthritis cartilage degeneration24. These
ﬁndings are consistent with our observation that Sik3 deletion or
pterosin B administration protected cartilage from osteoarthritic
change through activation of Hdac4, which prevented Mef2c
from activating the hypertrophy programme in articular
chondrocytes.
Prg4 is secreted by the most superﬁcial articular chondrocytes
and contributes to the lubrication of joints25. It also protects
cartilage against osteoarthritic change26,27, and its expression
is activated by the CRTC/CREB complex in articular
chondrocytes28. Sik3 anchors CRTC2 in the cytoplasm,
preventing CRTC2 from co-activating CREB in nuclei29. We
found that pterosin B treatment increased the expression level of
Prg4 in chondrocytes, at least in part, through CREB activation.
These ﬁndings collectively suggest that Sik3 deletion or pterosin B
administration protect cartilage from osteoarthritic change
through the CRTC/CREB pathway to activate Prg4 expression.
There are some limitations in this study. First, we cannot
exclude the possibility that thickening of growth plates affected
the course of osteoarthritis development in Sik3D/D mice. Second,
DMM surgery was performed on relatively young Sik3D/D mice.
An analysis of the effects of Sik3 deletion on aged mice with
DMM surgery would further clarify whether Sik3 affects the
development of osteoarthritis, since osteoarthritis is more
common in the elderly. Third, because we are not sure whether
injections of pterosin B were always done intraarticularly and
because pterosin B should be absorbed in the joint, we cannot
dismiss extraarticular or systemic effects. Fourth and ﬁnally, other
effects of pterosin B besides Sik3 inhibition cannot be ruled out as
providing protection from osteoarthritis. Nevertheless, our study
shows that SIK3 was activated in human osteoarthritic chon-
drocytes and that pterosin B inhibited hypertrophic changes and
increased PRG4 expression in human articular chondrocytes and
hiPSC-derived chondrocytes. Pterosin B is a compound in a
cooked plant consumed in human diets. On the basis of our
results, we suggest that SIK3 regulates the homeostasis of articular
cartilage and can be a target for the treatment of osteoarthritis,
and that pterosin B can be the lead compound for relevant drugs.
Methods
Ethics statement. All the experiments were approved by the institutional review
board, institutional animal committee (as appropriate) and the institutional
biosafety committee of Kyoto University, and the institutional review board of the
University of Toyama and Hachiya Orthopaedic Hospital.
Generation of mice. A cDNA encoding the modiﬁed estrogen receptor ligand
binding domain (ER) (provided by Dr M. Iwamoto, Children’s Hospital of
Philadelphia)30 was linked to the Cre sequence to create the CreER gene. The lacZ
gene in 742LacZInt31 was replaced with the CreER gene to create Col11a2-CreER,
and transgenic mice bearing the Col11a2-CreER were generated.
C57BL/6N ES cell clones, which contained the Sik3tm1a (EUCOMM) Hmgu allele,
were purchased from the European Conditional Mouse Mutagenesis Program
(EUCOMM). This allele includes targeting cassettes that were ﬂanked by FRT
recombination sites to allow removal by Flp recombinase and a pair of loxP
recombination sites around exon 5 of Sik3 (Supplementary Fig. 3a). These targeted
ES cells were injected into blastocysts of Slc:ICR mice to generate ES cell-derived
chimeras. Male chimeras were mated with C57BL/6NCrSlc female mice, and germ
line transmission was assessed by PCR. Heterozygous F1 mice were mated with B6-
Tg(CAG-FLPe)36 mice, which were provided by the RIKEN BRC through the
National Bio-Resource Project of MEXT, Japan, to delete the Neo and LacZ
cassettes and generate a ﬂoxed allele (Sik3ﬂox/þ ). Cre recombinases can induce
gene inactivation of the Sik3ﬂox allele by deleting exon 5 to generate a frame shift.
To generate Sik3 conditional knockout mice, Col11a2-CreER transgenic mice
and Sik3ﬂox/ﬂox mice were mated. Then, Col11a2-CreER; Sik3ﬂox/ﬂox and Rosa26-
stopﬂox-EYFP mice (Jackson Laboratory) were intercrossed and Col11a2-CreER;
Sik3ﬂox/ﬂox; Rosa26-stopﬂox-EYFP mice were generated. Col11a2-CreER; Sik3ﬂox/þ ;
Rosa26-stopﬂox-EYFP mice were used as controls.
Human articular cartilage samples and OARSI grading. Articular cartilages
were collected from 16 patients suffering from medial type knee osteoarthritis at
the time of total knee arthroplasty. A cartilage fragment was dissected from each
individual and subjected to histological analysis. Normal articular cartilage samples
were prepared from cadavers who had been free from joint disorders. The age and
gender of the individuals are shown in Supplementary Tables 2 and 3. Semiserial
sections were used for OARSI grading and immunostained for SIK3 and pSIK3.
OARSI grading was performed by one individual13. Use of human materials has
been approved by the institutional review board of Kyoto University, University of
Toyama and Hachiya Orthopaedic Hospital.
Histological analysis. For frozen sections, the samples were harvested without
ﬁxation and were immediately embedded in SCEM compound (SECTION-LAB).
The sections were prepared at 6-mm thickness with a Cryoﬁlm type 2c(9)
(SECTION-LAB) using a CM3050S cryomicrotome (Leica) according to the
method described by Kawamoto32.
For parafﬁn-embedded sections, the samples were dissected, ﬁxed in 4%
paraformaldehyde, processed and embedded in parafﬁn. The sections were
prepared at 6-mm thickness.
One individual measured the cartilage thickness and cell number of the
histological sections in a blinded manner.
Introduction of osteoarthritis model into Sik3D/D mice. A 100 mg per gram of
body weight tamoxifen (Sigma) was intraperitoneally injected into the peritoneal
spaces of 7-week-old Col11a2-CreER; Sik3ﬂox/ﬂox and Sik3ﬂox/ﬂox male mice daily
for 5 consecutive days. Then, the right knee joints of the mice were subjected to
DMM surgery33 or sham surgery (skin and joint capsule incision) at 8 weeks of age.
The mice were killed 8 weeks after the operation, and the knee joints were
subjected to histological analysis.
Rotarod performance test. The mice were put on a Rota-Rod (UGO BASILE).
The speed of the rotor drums were increased from 4 to 78 r.p.m. at 0.25 r.p.m. s 1
acceleration. The latency to fall from the rotor drums was recorded. The results
from three trials were averaged.
Preparation of reagents. A 100mg tamoxifen was dissolved in 2ml ethanol and
then suspended in 8ml corn oil. 4-OH tamoxifen (Sigma) was dissolved in ethanol
at a concentration of 0.5mM to prepare stock solution. Cyclophosphamide (Sigma)
and baﬁlomycin A1 (Sigma) were dissolved in DMSO at a concentration of
100mgml 1 and 100 mM, respectively, to prepare stock solution. CBP-CREB
interaction inhibitor (Cas 92–78–4, Merck Millipore) was also diluted in DMSO at
a concentration of 20mM as stock solution. Recombinant mouse IL-1b/IL-1F2
(R&D systems) were prepared at a concentration of 10 mgml 1 in sterile PBS with
0.1% bovine serum albumin. Ten millimolar ready to use MG132 solution (Sigma)
was purchased. Pterosin B was synthesized by Intelium Corp. (Supplementary
Fig. 5a). Pterosin B was dissolved in DMSO at a concentration of 100, 200 and
300mM for in vitro experiments and 900mM for mouse experiments to prepare
stock solution. These solutions were diluted with culture medium for in vitro
experiments.
Application of pterosin B to osteoarthritis model mice. DMM operations were
performed on the right knee joints of C57BL/6NCrSlc male mice 8 weeks or
13 weeks of age. Nine hundred millimolar pterosin B stock solution was diluted
with PBS to prepare the injection solution. Fifteen microlitres either of 900 mM
pterosin B injection solution or vehicle was injected into the intraarticular spaces of
the knee joints threetimes a week. After 8 or 13 weeks of injection, mice were killed,
and the knee joints were subjected to histological analysis.
OARSI scoring of articular cartilage of mouse knee joints. Twelve parafﬁn-
embedded semiserial sagittal sections with 40 mm intervals were prepared from the
medial compartment of each mouse knee joint. Sections were stained with safranin
O-fast Green-iron haematoxylin. Cartilage destruction was scored using the OARSI
scoring system34. OARSI scoring was performed by two independent scorers in a
blinded manner. Six consecutive sections out of 12 were selected to represent the
weight-bearing area of the femur and tibia, respectively, and were subjected to
OARSI scoring. The worst three scores were selected, and their average were
calculated. The scores of the femur and that of tibia were summed and designated
as the OARSI score for each knee. Synovial inﬂammation was scored as described
previously35.
Immunoﬂuorescent staining of histological sections. Frozen sections were ﬁxed
with 4% paraformaldehyde for 5min. After washing with TBST, the sections were
incubated with 10mgml 1 hyaluronidase (Sigma) at 37 C for 30min. After
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blocking with 10% goat normal serum (Nichirei Corporation), the sections were
incubated with primary antibody for 2 h at room temperature.
Parafﬁn-embedded sections were deparafﬁnized and incubated in 1mM EDTA
(pH 8.0) at 80 C for 15min to retrieve the antigen. Then, sections were treated
with 10mgml 1 hyaluronidase at 37 C for 30min. For detection of type
X collagen, the samples were treated with 20 mgml 1 Proteinase K (Life
Technologies) for 5min. After blocking with 10% goat normal serum, the
sections were incubated with primary antibody for 2 h at room temperature.
The primary antibodies used were as follows: mouse anti-type II collagen
(Thermo Scientiﬁc, 1:500), rabbit anti-type X collagen (Cosmo bio, 1:600),
rabbit anti-SOX9 (Santa Cruz Biotechnology, 1:200), anti-CD31 (Abcam, 1:20)
and chicken anti-GFP (for recognition of EYFP) (Abcam, 1:800). The
anti-pSIK3(pT163) antibodies were raised in rabbit against peptides corresponding
to residues (CSNLFTPGQLLK(pT)W, pT: phospho-Thr) of human SIK3 (Sigma,
1:2,000). Immune complexes were detected using secondary antibodies conjugated
to Alexa Fluor (Life Technologies, 1:1,000). DAPI (Dojindo Molecular
Technologies, 1:1,000) was used.
BrdU staining. The mice were intraperitoneally injected with BrdU labelling
reagent (10 ml g 1 body weight, Life Technologies) 3 h before being killed. The
parafﬁn-embedded sections were prepared. The incorporated BrdU was detected
using a BrdU staining kit (Life Technologies) to distinguish actively proliferating
cells.
Pellet culture of mouse primary chondrocytes. Primary chondrocytes were
prepared from newborn mice as described previously36. Brieﬂy, epiphyseal cartilage
was dissected from the knee joints and femoral heads of newborn mice, predigested
with 3mgml 1 collagenase D (Roche) in Dulbecco’s Modiﬁed Eagle Medium
(DMEM) (Sigma) at 37 C for 90min and further digested in 0.5mgml 1
collagenase D at 37 C overnight. A total of 5 105 primary chondrocytes were
plated in a 10-cm dish and cultured in DMEM, 10% FBS, 2mM L-Glu (Life
Technologies), 1% penicillin–streptomycin (Life Technologies) for 10 days. A total
0.5 mM 4-OH tamoxifen was added for the ﬁrst 5 days. Then, 5 105 primary
chondrocytes were transferred into a 15-ml tube (Thermo Fisher Scientiﬁc) and
centrifuged at 500 g for 10min. After 3 days incubation in the same medium in the
tubes, the resulting cell pellets were transferred into petri dishes and incubated in
the same medium in the presence or absence of various concentrations of pterosin
B for a further 4 weeks.
Organ culture of mouse metatarsal primordial cartilage. Second, third and
fourth metatarsal primordial cartilage of forelimb bud was cultured as described
previously37. Metatarsal cartilage was dissected from mouse embryos at 15.5 days
postcoitum. One metatarsal was organ-cultured in each well. From the next day,
the metatarsals were treated with 300 mM pterosin B or vehicle for 1 week.
Metatarsals were subjected to histological analysis.
Pellet culture of human articular chondrocytes. Cartilage fragments were dis-
sected from the less damaged area of the articular surface in the posterior condyle
of the distal femur that was discarded at the time of total knee replacement surgery.
The cartilage fragments were minced and treated with 0.25% trypsin at 37 C for
1 h. Cartilage fragments were further digested in 4mgml 1 collagenase D at 37 C
overnight. A total of 1 106 human articular chondrocytes were cultured in a
10-cm dish in chondrogenic medium, which consisted of DMEM, 10% FBS,
1% insulin–transferrin–selenium solution (ITS, Life Technologies), 10 ngml 1
recombinant human TGF-b1 (Peprotech), 100 nM dexamethasone (Sigma),
50mgml 1 L(þ )-ascorbic acid (Nacalai tesque), 1mM sodium pyruvate (Life
Technologies) and 1% penicillin–streptomycin for 7 days. Then, 5 105 primary
human chondrocytes were transferred into a 15-ml tube and centrifuged at 500 g
for 10min. After 3 days incubation in the same medium in the tubes, the resulting
cell pellets were transferred into a petri dish and incubated in the same medium for
a further 8 weeks. Finally, the medium was replaced with hypertrophic medium
(DMEM supplemented with 1% FBS, 1% ITS, 100 ngml 1 BMP-2 (Peprotech),
10 ngml 1 GDF-5 (PTT), 1mM 3,3,5-Triiodo-L-thyronine (T3) (Sigma),
50mgml 1 L(þ )-Ascorbic acid, 10 nM dexamethasone, 10mM b-glyceropho-
sphate (Sigma) and 1% penicillin–streptomycin) in the presence or absence of
300mM pterosin B for an additional 2 weeks.
Hypertrophic differentiation of human iPSC-derived cartilage. Human
iPSCs (hiPSCs) were chondrogenically differentiated to produce hiPSC-derived
cartilaginous particles as described previously38. The hiPSCs were transferred
and then maintained in a feeder-free medium, Essential 8 (Invitrogen) with
50 units ml 1 penicillin and 50mgml streptomycin, in 3.5-cm Matrigel-coated
dishes. The hiPSCs formed high-density cell colonies which consisted of 1–2 105
cells 10–15 days after the start of maintenance under the feeder-free culture
conditions. Subsequently, the chondrogenic differentiation of iPSCs was
performed. The hiPSCs were initially differentiated into mesendodermal cells in
DMEM/F12 (Sigma) with 10 ngml 1 of Wnt3A (R&D), 10 ngml 1 of Activin A
(R&D), 1% ITS, 1% FBS and 50 units and 50mgml 1 of penicillin and
streptomycin, respectively for 3 days. On day 3, the medium was changed to the
basal medium (DMEM with 1% ITS, 1% FBS, 2mM L-glutamine (Invitrogen),
1 10 4M nonessential amino acids (Invitrogen), 1mM Na pyruvate
(Invitrogen), 50 units of penicillin and 50mgml 1 of streptomycin) supplemented
with 50mgml 1 of ascorbic acid, 10 ngml 1 of BMP2, 10 ngml 1 of TGF-b1 and
10 ngml 1 of GDF5, which was intended to commit the cells to the chondrocytic
lineage. A total of 10 ngml 1 of bFGF (WAKO) was added to the chondrogenic
medium from day 3 to day 14 to increase the cell proliferation. Chondrogenic cells
form multilayered nodules by day 14. The nodules were physically separated from
the bottom of the dishes to form particles, which were then transferred to a
suspension culture in 3.5-cm petri dishes on day 14. The cells in the particles
produce cartilaginous extracellular matrix, resulting in the particles becoming
cartilaginous tissue in suspension culture. The culture medium was changed
every 2–7 days. The hiPSC-derived cartilaginous particles on day 56 were
cultured in the hypertrophic medium in the presence or absence of 300 mM
pterosin B for 4 weeks.
Real-time RT–PCR. The samples were frozen in liquid nitrogen and crushed
by a Multibead shocker (Yasui Kikai). RNA was extracted by using ISOGEN
(Nippon gene). For the real-time RT–PCR analyses, 500 ng of total RNA was
reverse-transcribed into ﬁrst-strand cDNA by using ReverTra Ace (Toyobo) and
random primers. PCR ampliﬁcation was performed in a reaction volume of 10 ml
containing 1 ml cDNA and 5 ml SYBR FAST qPCR Master Mix (Kapa Biosystems)
using 7900HT (Life Technologies). The primers used are listed in Supplementary
Tables 4 and 5.
Sequence analysis of mRNA-seq. Primary chondrocytes of Col11a2-CreER;
Sik3ﬂox/ﬂox mice were cultured in DMEM, 10% FBS medium for 5 days on a
culture dish. Then, the chondrocytes were centrifuged and incubated in tubes
for 3 days. The resulting cell pellets were incubated in the same medium in the
presence or absence of 300 mM pterosin B for another 4 weeks. RNAs were
extracted from the cultured chondrocyte pellets using QIAzol Lysis Reagent
(Qiagen) and miRNeasy Mini Kit (Qiagen). RNAs were also extracted from various
mouse tissues.
A 100 ng of total RNA was subjected to library preparation using KAPA
stranded mRNA-seq Kits (KAPA Biosystems, Woburn, MA), according to the
manufacturer’s instruction. The libraries were sequenced in 100-cycle single-read
mode of HiSeq2500. All sequence reads were extracted in FASTQ format using
BCL2FASTQ Conversion Software 1.8.4 in the CASAVA 1.8.2 pipeline. The
sequence reads were mapped to mm9 reference genes, using Tophat v2.0.14.
Gene expression values were calculated and normalized using rpkmforgenes
(10 December 2012). Averages of gene expression values from triplicate cultured
chondrocyte pellet samples were calculated. Two-way hierarchical clustering of
gene expressions in cultured chondrocyte pellets (n¼ 3) and tissues (n¼ 1) was
conducted using the Euclidian distance and the ward method of hclust function
in R3.2.1.
Gene Ontology and pathway analysis. Genes differentially expressed between
control and pterosin B-treated cells were statistically selected using DEseq2
software (|log2FC|41, FDRo0.05). GO terms over-represented in the gene list
selected by DEseq2 were retrieved by hypergeometric tests using GOstats 2.36.0 of
R3.2.2 with the annotation packages GO.db 3.2.2 and org.Mm.eg.db 3.2.3. Pathway
analysis was performed by hypergeometric tests of differentially expressed genes
using KEGGproﬁle 1.12.0 of R3.2.2 with the annotation packages KEGG.db 3.2.2
and org.Mm.eg.db 3.2.3.
Cell culture. HEK293FT cells (Invitrogen) were grown in DMEM containing 10%
FBS. ATDC5 cells (Riken Cell Bank) were cultured with DMEM/Nutrient F-12
Ham (Sigma) containing 5% FBS. GAL4-MEF2C and GAL4-CRTC2 luciferase
reporter assays were performed as described previously39.
Microscope. Images were acquired on an inverted microscope (Eclipse Ti; Nikon)
equipped with cameras (DS-Fi1; Nikon and C4742-80-12AG; Hamamatsu
photonics), the NIS Elements software program (Nikon) and BZ-9000 (Keyence).
Immunoblot analysis. Primary chondrocytes were lysed in RIPA buffer
containing protease inhibitor and phosphatase inhibitor (both Roche) and
subjected to SDS–polyacrylamide gel electrophoresis. The separated proteins were
then electroblotted and immunostained with rabbit anti-Sik3 antibody (1:500,
Abcam), rabbit anti-phosphorylated HDAC4 (Ser246)/HDAC5 (Ser259)/HDAC7
(Ser155) antibody (Cell Signaling, 1:600), rabbit anti-HDAC4 antibody (Abcam,
1:250), rabbit anti-CRTC1 (Novus Biologicals, 1:1,000) and rabbit anti-GAPDH
(Santa Cruz, 1:400). The ECL system and LAS3000 (both GE Healthcare) were used
for chemiluminescent immunodetection.
Full blotting images corresponding to the immunoblottings shown in the main
and Supplementary Figures are provided as Supplementary Fig. 9.
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Statistical analysis. Data are shown as averages and standard deviations.
We used analysis of variance followed by the Tukey–Kramer post hoc test.
In some experiments, the Student’s t-test (two-sided) was used when homogenous
variances were assumed (P40.05) by the F test, and Welch’s t-test was used when
homogenous variances were not assumed (Po0.05) by the F test. In osteoarthritis
model experiments, score values were analysed using nonparametric statistical
methods (Mann–Whitney test). P values o0.05 were considered statistically
signiﬁcant.
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